Table 4.

Comparison between the present study and the previous studies of LAHCC

Reference	Year	n	Treatment Method	OS
Kudo M, et al. [3]	2018	250	Lenvatinib	Median OS: 11.5 months
Bruix J, et al. [4]	2012	108	Sorafenib	Median OS: 8.1 months
Yoon SM, et al. [5])	2018	45	Sorafenib	Median OS: 9.9 months
Kodama K, et al. [21]	2018	36	Sorafenib	Median OS: 5.3 months
Kodama K, et al. [21]	2018	36	HAIC with RT	Median OS: 9.9 months
Yoon SM, et al. [5]	2018	45	TACE with RT	Median OS: 12.7 months
Zhang X, et al.a [22]	2017	21–604	Sorafenib	Median OS: 7.0–13.0 months
Kudo M, et al. [15]	2019	1101	Surgery	3y-OS: 40%
Liu PH, et al. [23]	2014	247	Surgery	3y-OS: 68%
Shi J, et al. [24]	2010	406	Surgery	3y-OS: 13%
Komatsu S, et al. [25]	2017	19	Particle RT (proton beam therapy and C-ion RT)	Median OS: 24.6 months
Present study		11	C-ion RT	Median OS: 36.4 months, 3y-OS: 64%

^aReview article

^†Abbreviations: C-ion RT carbon ion radiotherapy, HAIC hepatic arterial infusion chemotherapy, OS overall survival, RT radiotherapy, TACE transarterial chemoembolization, 3y-OS 3-year overall survival